Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinshubao Capsules (心舒宝胶囊) is a Traditional Chinese Medicine (TCM) formulation approved for the treatment of cardiovascular diseases, particularly coronary heart disease and angina pectoris. The product is composed of several herbal extracts, including Hawthorn (*Crataegus pinnatifida*), Danshen (*Salvia miltiorrhiza*), Ginseng (*Panax ginseng*), Kudzu root (*Pueraria lobata*), and synthetic Borneol. Its therapeutic mechanism involves promoting blood circulation, resolving blood stasis, and regulating Qi to alleviate pain. Clinically, it is used to relieve symptoms such as chest tightness, palpitations, and shortness of breath associated with Qi deficiency and blood stasis. The drug is developed and manufactured by companies including Hefei Huafang Pharmaceutical Technology and is recognized in the Chinese Pharmacopoeia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xinshubao Capsules.